Anakinra dosing

The recommended dose of anakinra is 100 mg/day administered at approximately the same time daily by subcutaneous injection. Higher doses did not result in a higher response. Administer the dose at approximately the same time every day. 

Pharmacokinetics The absolute bioavailability after a 70 mg subcutaneous bolus injection in healthy subjects (n = 11) is 95%. In subjects with RA, maximum plasma concentrations occurred 3 to 7 hours after subcutaneous administration of anakinra at clinically relevant doses (1 to 2 mg/kg n = 18) the terminal half-life ranged from 4 to 6 hours. In RA patients, no unexpected accumulation was observed after daily subcutaneous doses for up to 24 weeks. The estimated clearance increased with increasing Ccr and body weight. 

Pharmacokinetics No accumulation of anakinra in tissues or organs was observed after daily subcutaneous doses. Excreted in urine. Half-life 4-6 hr. 

KINERET (Anakinra) [E. coli expressed recombinant, Amgen Liquid 100 mg prefilled single dose syringe 100 mg per 0.67 mL (pH 6.5) Per Syringe 1.29 mg sodium citrate 5.48 mg sodium chloride 0.12 mg disodium EDTA... 

Immunologic An IgE-mediated anaphylactic reaction has been attributed to anakinra in a 46-year-old Indian woman with rheumatoid arthritis who had had an urticarial rash and infusion reactions after three doses of infliximab, and autoantibodies, worsening Raynaud s phenomenon, and digital microinfarcts after treatment with etanercept for 1 year [83 ]. Skin prick tests were positive to both anakinra and histamine. She then had an urticarial reaction to adalimumab. 

---